Results 181 to 190 of about 216,694 (240)

Myelin-specific IL2 + T-cells are associated with last occurring relapse severity in relapsing-remitting multiple sclerosis. [PDF]

Sci Rep
Zilkha-Falb R, Drori T, Shwartz K, Gurevich M.   +3 more
europepmc   +1 more source

Effectiveness and Safety of Rituximab in Filipino Patients With Relapsing-Remitting Multiple Sclerosis: A Real-World Retrospective Cohort Study in a Resource-Limited Setting. [PDF]

Cureus
Co APC, De la Paz FGE, Aninang MT, Del Mundo MES, Nobleza CMN, Damian LF.   +5 more
europepmc   +1 more source

Association of the along‑perivascular space (ALPS) index and white matter volume with cognitive dysfunction in relapsing‑remitting multiple sclerosis patients. [PDF]

BMC Neurol
Song Y, Zhao H, Wu Q, Xie S, He J, Bai R, Wang S, Gao Y.   +7 more
europepmc   +1 more source

NX210c Demonstrates Therapeutic Potential to Restore Blood-Brain Barrier in a QSP Model of Relapsing-Remitting Multiple Sclerosis. [PDF]

Int J Mol Sci
Russo G, Sips F, Catozzi S, Bambury P, Janus A, Torchia M, Di Salvatore V, Emili L, Röshammar D, Pappalardo F, Godfrin Y.   +10 more
europepmc   +1 more source

Video Head Impulse Testing in Relapsing Remitting Multiple Sclerosis: Evaluation of Canal Gains, Asymmetry, and Corrective Saccades with Cerebellar Lesions. [PDF]

J Otol
Tahir E, Küçüköner A, Uştu EK, Şen S, Terzi M.   +4 more
europepmc   +1 more source

Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years. [PDF]

J Neurol Neurosurg Psychiatry
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Greco A, Sun Z, Lasky T, TOP Investigators.   +8 more
europepmc   +1 more source

Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies. [PDF]

Drugs Real World Outcomes
Pastore F, Domenicone E, DellOro P, Lefort C.   +3 more
europepmc   +1 more source

Therapeutic Outcomes of Fingolimod and Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: A Real-World Study from Jordan. [PDF]

Medicina (Kaunas)
Al Anber A, Abu Al Karsaneh O, Abuquteish D, Abdallah O, Issa MA, Sa'adeh M, Kilani D.   +6 more
europepmc   +1 more source

Overexpression of ITGB3 in Peripheral Blood Mononuclear Cells of Relapsing-Remitting Multiple Sclerosis Patients. [PDF]

Int J Mol Sci
Sancho GBV, Buendia-Corona RE, Reyes-Mata MP, Mireles-Ramírez MA, Griñán-Ferré C, Pallàs M, Márquez-Aguirre AL, Pavon L, Arias-Carrión O, Guerrero-García JJ, Ortuño-Sahagún D.   +10 more
europepmc   +1 more source

Selected Serum Biomarkers in Patients with Relapsing-Remitting Multiple Sclerosis-A 3-Year Prospective Pilot Study. [PDF]

Med Sci (Basel)
Puz P, Maciejowska K, Gendosz de Carrillo D, Janik M, Lasek-Bal A.   +4 more
europepmc   +1 more source